"Anticoagulation Management and Heparin Resistance During Cardiopulmona" by R. M. Sniecinski, E. Bennett-Guerrero et al.
 

Publication Date

2019

Journal Title

Anesth Analg

Abstract

We surveyed Society of Cardiovascular Anesthesiologists members regarding anticoagulation practices for cardiopulmonary bypass and attitudes on heparin resistance. Of 550 respondents (18.5% response rate), 74.9% (95% CI, 71.3%-78.5%) used empiric weight-based dosing of heparin, and 70.7% (95% CI, 66.9%-74.5%) targeted an activated clotting time of either 400 or 480 seconds to initiate cardiopulmonary bypass. Of note, 17.1% (95% CI, 13.9%-20.2%) of respondents reported activated clotting time targets lower than those recommended by recent 2018 Society of Thoracic Surgeons/Society of Cardiovascular Anesthesiologists/American Society of Extracorporeal Technology guidelines or failed to monitor heparin effects at all. When heparin resistance was encountered, 54.2% of respondents (95% CI, 50.0%-58.4%) administered antithrombin concentrates as a first-line therapy.

Volume Number

129

Issue Number

2

Pages

e41 - e44

Document Type

Article

Status

Faculty

Facility

School of Medicine

Primary Department

Anesthesiology

PMID

30540616

DOI

10.1213/ANE.0000000000003981


Share

COinS